36 Participants Needed

Thiotepa + Stem Cell Transplant for Lymphoma

(CNS-PHLAT Trial)

AF
Overseen ByAmanda F Cashen, M.D.
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Washington University School of Medicine
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

What data supports the effectiveness of the treatment Thiotepa + Stem Cell Transplant for Lymphoma?

Research shows that thiotepa-based conditioning regimens, when used in autologous stem cell transplants for lymphoma, have similar effectiveness and safety compared to traditional regimens like BEAM. This suggests that thiotepa can be a valuable alternative, especially for older patients or those with more prior treatments.12345

Is the combination of Thiotepa and Stem Cell Transplant generally safe for humans?

Research shows that using thiotepa in combination with stem cell transplants for lymphoma has a safety profile similar to other common regimens, with no significant differences in survival or complications. However, some studies noted serious side effects like respiratory issues and infections, especially at higher doses or in heavily pretreated patients.14567

What makes the Thiotepa + Stem Cell Transplant treatment unique for lymphoma?

The Thiotepa + Stem Cell Transplant treatment is unique because it uses thiotepa, a drug that can penetrate the central nervous system, making it potentially more effective for lymphomas that affect this area. This treatment is an alternative to the conventional BEAM regimen and has shown comparable efficacy and safety, with a possible advantage for older patients.12458

What is the purpose of this trial?

A serious consequence of systemic diffuse large B-cell lymphoma (DLBCL) is secondary central nervous system (CNS) relapse, which occurs in approximately 5% of all patients. Many CNS relapses occur within the first year after completion of frontline treatment and are associated with significantly increased mortality; thus, it is important to tailor frontline treatment to provide prophylaxis against CNS relapse in those patients who are determined to be high-risk.Autologous stem cell transplantation (ASCT) is standard of care for patients with DLBCL who relapse one year or more after first remission, and it has been shown to improve progression-free survival for patients with primary CNS lymphoma.The four-drug BEAM regimen (carmustine, etoposide, cytarabine, and melphalan) is the preferred conditioning regimen for DLBCL patients undergoing ASCT; however, patients with primary CNS lymphoma receive thiotepa plus carmustine as their conditioning regimen due to its better CNS penetration.This study tests the hypothesis that consolidation thiotepa/carmustine ASCT in first complete remission will reduce the risk of CNS relapse in transplant-eligible patients with DLBCL with no prior CNS disease at high risk of secondary CNS recurrence.

Research Team

Amanda F. Cashen, MD - Washington ...

Amanda Cashen, MD

Principal Investigator

Washington University School of Medicine

Eligibility Criteria

This trial is for high-risk patients with Diffuse Large B-cell Lymphoma (DLBCL) who are in their first complete remission and eligible for a stem cell transplant. It's not suitable for those with prior central nervous system disease or other conditions that would exclude them from safely receiving the treatments being tested.

Inclusion Criteria

Agree to use adequate contraception if of childbearing potential
I have been diagnosed with a type of aggressive B-cell lymphoma.
I can take care of myself but might not be able to do heavy physical work.
See 4 more

Exclusion Criteria

History of allergic reactions to specific compounds
Pregnant and/or breastfeeding
I do not have another cancer that could affect this treatment's safety or results.
See 4 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Induction Chemotherapy

Participants receive anthracycline-based induction chemotherapy regimen per standard of care for 6 cycles

12-18 weeks

Conditioning and Transplantation

Participants undergo conditioning with thiotepa and carmustine followed by autologous stem cell transplantation (ASCT)

1-2 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Autologous Stem Cell Transplant
  • Carmustine
  • Thiotepa
Trial Overview The study is testing if using Thiotepa and Carmustine as part of an autologous stem cell transplant can prevent brain relapse in DLBCL patients at high risk. This approach is compared to the standard BEAM regimen, which includes different chemotherapy drugs.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Anthracycline-based induction chemotherapy + ASCT + Thiotepa + CarmustineExperimental Treatment4 Interventions
* Patients should receive induction treatment with anthracycline-based chemotherapy regimen per standard of care (6 cycles). Management, dose delays, and dose modifications will be per standard of care and treating physician discretion; administration of anthracycline-based induction therapy is not dictated by the study. Patients who have a PR by PET criteria but whose residual abnormality on PET is unlikely to represent residual disease may proceed to ASCT. * After confirmation of complete response (CR) following induction therapy, patients will begin conditioning with thiotepa (days -5 and -4) and carmustine (day -6), followed by ASCT on day 0.

Autologous Stem Cell Transplant is already approved in United States, European Union, Canada for the following indications:

🇺🇸
Approved in United States as Autologous Stem Cell Transplant for:
  • Multiple Myeloma
  • Non-Hodgkin Lymphoma
  • Hodgkin Lymphoma
  • Leukemia
🇪🇺
Approved in European Union as Autologous Stem Cell Transplant for:
  • Multiple Myeloma
  • Non-Hodgkin Lymphoma
  • Hodgkin Lymphoma
  • Leukemia
🇨🇦
Approved in Canada as Autologous Stem Cell Transplant for:
  • Multiple Myeloma
  • Non-Hodgkin Lymphoma
  • Hodgkin Lymphoma
  • Leukemia

Find a Clinic Near You

Who Is Running the Clinical Trial?

Washington University School of Medicine

Lead Sponsor

Trials
2,027
Recruited
2,353,000+

Findings from Research

The TECAM conditioning regimen, which includes thiotepa and cyclophosphamide, showed comparable efficacy and safety to the conventional BEAM regimen in a study of 125 patients undergoing autologous stem cell transplantation for B-cell lymphomas, with 3-year progression-free survival rates of 49% for TECAM and 62% for BEAM.
TECAM was particularly effective for older patients, with 23% of TECAM recipients over 65 years old achieving similar outcomes to younger patients, suggesting it may be a suitable option for older individuals who have had more prior treatments.
Replacing carmustine by thiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin's and non-Hodgkin's B-cell lymphoma.Joffe, E., Rosenberg, D., Rozovski, U., et al.[2019]
In a retrospective study of 56 patients with primary central nervous system lymphoma (PCNSL) undergoing autologous stem cell transplant (ASCT), there was no significant difference in progression-free survival or overall survival between those receiving thiotepa-based conditioning and those receiving BEAM conditioning, despite the thiotepa group having higher-risk disease features.
The study found that the disease response status before transplant was a critical factor influencing outcomes, with patients in complete remission showing significantly better overall survival rates compared to those with partial response, highlighting the importance of pre-transplant disease status.
Outcomes of Autologous Stem Cell Transplant Consolidation in Primary Central Nervous System Lymphoma: A Mayo Clinic Experience.Khurana, A., Micallef, IN., LaPlant, BR., et al.[2021]
In a study involving 77 patients with Hodgkin's disease and non-Hodgkin's lymphoma, high-dose etoposide combined with either fractionated total body irradiation (TBI) or carmustine before autologous bone marrow transplantation showed promising results, with a 1-year survival rate of 85% for TBI patients and 79% for carmustine patients.
Despite the effectiveness, there was an 8% rate of toxic deaths, all occurring in the carmustine group, highlighting a safety concern associated with this treatment regimen.
The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data.Horning, SJ., Chao, NJ., Negrin, RS., et al.[2020]

References

Replacing carmustine by thiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin's and non-Hodgkin's B-cell lymphoma. [2019]
Outcomes of Autologous Stem Cell Transplant Consolidation in Primary Central Nervous System Lymphoma: A Mayo Clinic Experience. [2021]
The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data. [2020]
A Retrospective Comparison of TECAM and BEAM Conditioning Regimens Before Autologous Hematopoietic Stem Cell Transplant in Lymphoma Patients: Efficacy and Toxicity. [2019]
Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT. [2023]
Impact of thiotepa dose-intensity in primary diffuse large B-cell lymphoma of the central nervous system undergoing autologous hematopoietic cell transplant with thiotepa/carmustine conditioning. [2023]
High-dose tri-alkylator chemotherapy with autologous stem cell rescue in patients with refractory malignancies. [2019]
An expanded-access clinical study of thiotepa (DSP-1958) high-dose chemotherapy before autologous hematopoietic stem cell transplantation in patients with malignant lymphoma. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security